JP3869092B2 - ヒトテロメラーゼ触媒性サブユニット - Google Patents

ヒトテロメラーゼ触媒性サブユニット Download PDF

Info

Publication number
JP3869092B2
JP3869092B2 JP28618297A JP28618297A JP3869092B2 JP 3869092 B2 JP3869092 B2 JP 3869092B2 JP 28618297 A JP28618297 A JP 28618297A JP 28618297 A JP28618297 A JP 28618297A JP 3869092 B2 JP3869092 B2 JP 3869092B2
Authority
JP
Japan
Prior art keywords
htrt
telomerase
cells
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP28618297A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10234384A (ja
Inventor
アール． セチ トーマス
リングナー ジョーチム
トオル ナカムラ
ビー． チャップマン カレン
ビー． モリン グレッグ
ビー． ハーレイ カルビン
エイチ． アンドリューズ ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27575511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3869092(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/851,843 external-priority patent/US6093809A/en
Priority claimed from US08/854,050 external-priority patent/US6261836B1/en
Priority claimed from US08/912,951 external-priority patent/US6475789B1/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of JPH10234384A publication Critical patent/JPH10234384A/ja
Application granted granted Critical
Publication of JP3869092B2 publication Critical patent/JP3869092B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
JP28618297A 1996-10-01 1997-10-01 ヒトテロメラーゼ触媒性サブユニット Expired - Lifetime JP3869092B2 (ja)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US72464396A 1996-10-01 1996-10-01
US08/724,643 1996-10-01
US84441997A 1997-04-18 1997-04-18
US08/844,419 1997-04-18
US84601797A 1997-04-25 1997-04-25
US08/846,017 1997-04-25
US08/851,843 1997-05-06
US08/851,843 US6093809A (en) 1996-10-01 1997-05-06 Telomerase
US08/854,050 1997-05-09
US08/854,050 US6261836B1 (en) 1996-10-01 1997-05-09 Telomerase
US91131297A 1997-08-14 1997-08-14
US91550397A 1997-08-14 1997-08-14
US08/911,312 1997-08-14
US08/912,951 1997-08-14
US08/915,503 1997-08-14
US08/912,951 US6475789B1 (en) 1996-10-01 1997-08-14 Human telomerase catalytic subunit: diagnostic and therapeutic methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP32016998A Division JP4070331B2 (ja) 1996-10-01 1998-10-15 ヒトテロメラーゼ触媒性サブユニットプロモーター
JP2000227474A Division JP2001081042A (ja) 1996-10-01 2000-07-27 ヒトテロメラーゼ触媒性サブユニット

Publications (2)

Publication Number Publication Date
JPH10234384A JPH10234384A (ja) 1998-09-08
JP3869092B2 true JP3869092B2 (ja) 2007-01-17

Family

ID=27575511

Family Applications (7)

Application Number Title Priority Date Filing Date
JP28618297A Expired - Lifetime JP3869092B2 (ja) 1996-10-01 1997-10-01 ヒトテロメラーゼ触媒性サブユニット
JP51680298A Pending JP2001523947A (ja) 1996-10-01 1997-10-01 テロメラーゼ逆転写酵素
JP51690998A Pending JP2001510985A (ja) 1996-10-01 1997-10-01 ヒトテロメラーゼ触媒性サブユニット
JP32016998A Expired - Lifetime JP4070331B2 (ja) 1996-10-01 1998-10-15 ヒトテロメラーゼ触媒性サブユニットプロモーター
JP11042410A Pending JPH11313689A (ja) 1996-10-01 1999-02-19 ヒトテロメラ―ゼ触媒性サブユニット
JP2000227474A Withdrawn JP2001081042A (ja) 1996-10-01 2000-07-27 ヒトテロメラーゼ触媒性サブユニット
JP2008194208A Expired - Lifetime JP4852576B2 (ja) 1996-10-01 2008-07-28 ヒトテロメラーゼ触媒性サブユニット

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP51680298A Pending JP2001523947A (ja) 1996-10-01 1997-10-01 テロメラーゼ逆転写酵素
JP51690998A Pending JP2001510985A (ja) 1996-10-01 1997-10-01 ヒトテロメラーゼ触媒性サブユニット
JP32016998A Expired - Lifetime JP4070331B2 (ja) 1996-10-01 1998-10-15 ヒトテロメラーゼ触媒性サブユニットプロモーター
JP11042410A Pending JPH11313689A (ja) 1996-10-01 1999-02-19 ヒトテロメラ―ゼ触媒性サブユニット
JP2000227474A Withdrawn JP2001081042A (ja) 1996-10-01 2000-07-27 ヒトテロメラーゼ触媒性サブユニット
JP2008194208A Expired - Lifetime JP4852576B2 (ja) 1996-10-01 2008-07-28 ヒトテロメラーゼ触媒性サブユニット

Country Status (20)

Country Link
US (4) US6166178A (enExample)
EP (6) EP0932686A2 (enExample)
JP (7) JP3869092B2 (enExample)
KR (2) KR20000048820A (enExample)
CN (3) CN1291231B (enExample)
AT (3) ATE449851T1 (enExample)
AU (2) AU4803697A (enExample)
BR (3) BR9711844A (enExample)
CA (3) CA2266752A1 (enExample)
DE (5) DE69723531T3 (enExample)
EA (2) EA199900349A1 (enExample)
ES (1) ES2205132T5 (enExample)
FI (1) FI990655A7 (enExample)
FR (1) FR2757177A1 (enExample)
GB (2) GB2321642B8 (enExample)
IL (2) IL129222A0 (enExample)
NO (2) NO319982B1 (enExample)
NZ (1) NZ334709A (enExample)
SG (1) SG94355A1 (enExample)
WO (2) WO1998014593A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081042A (ja) * 1996-10-01 2001-03-27 Geron Corp ヒトテロメラーゼ触媒性サブユニット

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US6545133B1 (en) 1995-08-04 2003-04-08 Geron Corporation Methods for purifying telomerase
US6517834B1 (en) 1995-08-04 2003-02-11 Geron Corporation Purified telomerase
US6582904B2 (en) 1995-11-16 2003-06-24 Michael W. Dahm Method of quantifying tumour cells in a body fluid and a suitable test kit
US6881571B1 (en) * 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US6607898B1 (en) 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6777203B1 (en) * 1997-11-19 2004-08-17 Geron Corporation Telomerase promoter driving expression of therapeutic gene sequences
US6261836B1 (en) * 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6444650B1 (en) * 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US7390891B1 (en) * 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
EP0942991A2 (en) * 1996-11-26 1999-09-22 Baylor College Of Medicine Identification of inhibitors that prevent access of telomerase to chromosomal terminus
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
EP0990037A2 (de) * 1997-06-20 2000-04-05 Bayer Ag Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung
CA2294782A1 (en) * 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
EP1571215A3 (en) * 1997-07-01 2007-10-31 Cambia Biosystems LLC Vertebrate telomerase genes and proteins and uses thereof
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
WO1999027113A1 (en) * 1997-11-26 1999-06-03 Geron Corporation Mouse telomerase reverse transcriptase
DE19757984A1 (de) * 1997-12-24 1999-07-01 Bayer Ag Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung
DE19804372A1 (de) * 1998-02-04 1999-08-05 Michael W Dr Dr Dahm Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
AU754278B2 (en) * 1998-03-26 2002-11-07 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibody against human telomerase catalytic subunit
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US20030105315A1 (en) * 1998-04-09 2003-06-05 Metagen Pharmaceuticals Gmbh Human nucleic acid sequences from ovarian tumor tissue
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
ATE347904T1 (de) 1998-10-29 2007-01-15 Dana Farber Cancer Inst Inc Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert
GB9900298D0 (en) * 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
EP1149161A2 (de) * 1999-01-22 2001-10-31 Humboldt-Universität zu Berlin Universitätsklinikum Charite; GEGEN DIE KATALYTISCHE UNTEREINHEIT DER HUMANEN TELOMERASE (hTERT) GERICHTETE RIBOZYME
ES2220448T3 (es) * 1999-02-04 2004-12-16 Geron Corporation Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa.
US7314926B1 (en) 1999-04-08 2008-01-01 Antisoma Research Limited Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
EP1171612A2 (en) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-specific cancer vaccine
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
DE19916929A1 (de) * 1999-04-15 2000-10-19 Bayer Ag Ein automatisierbarer Schnelltest zum Nachweis von Krebserkrankungen auf der Basis von Telomerase(hTC) mRNA mit spezifischen Primern und Sonden
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
US20050255596A1 (en) * 1999-09-07 2005-11-17 West Michael D Methods of repairing tandemly repeated DNA sequences and extending cell life-span nuclear transfer
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
FR2798673B1 (fr) * 1999-09-16 2004-05-28 Exonhit Therapeutics Sa Methodes et compositions pour la detection d'evenements pathologiques
US6399384B1 (en) 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
AU1309101A (en) * 1999-11-16 2001-05-30 Kyowa Hakko Kogyo Co. Ltd. Method of searching for substance inhibiting binding between telomerase subunits
GB9927353D0 (en) * 1999-11-19 2000-01-19 Cantab Pharma Res Virus preparation and use
US7414170B2 (en) 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7074983B2 (en) 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US6664046B1 (en) * 1999-12-16 2003-12-16 Roche Molecular Systems, Inc. Quantitation of hTERT mRNA expression
KR20010096991A (ko) * 2000-04-19 2001-11-08 임정빈 텔로머레이즈의 프로모터에 특정하게 결합하는더블유티이1 절편, 그 유전자, 발현벡터 및 그것을 이용한세포성장 억제 방법
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
IT1318504B1 (it) * 2000-05-08 2003-08-27 Talent Srl Metodo e apparecchiatura per la diagnosi precoce di tumori vescicalisu campioni di urina.
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
EP1158055A1 (fr) 2000-05-26 2001-11-28 Xu Qi University of Teaxs Laboratoire de Leucémie Chen Méthode pour le diagnostic de cancers
US7078491B1 (en) 2000-09-21 2006-07-18 Amgen Inc. Selective binding agents of telomerase
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
WO2002048319A1 (en) * 2000-12-14 2002-06-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Telomerase immortalized human liver cell lines
US7491534B2 (en) 2000-12-22 2009-02-17 Kirin Holdings Kabushiki Kaisha Methods for altering cell fate to generate T-cells specific for an antigen of interest
AU2002232858B2 (en) 2000-12-22 2007-01-11 Sab, Llc Methods for cloning mammals using reprogrammed donor chromatin or donor cells
US6906237B2 (en) * 2001-02-27 2005-06-14 G. Scott Herron Vivo assay for anti angiogenic compounds
US20040063922A1 (en) * 2001-04-17 2004-04-01 Conrad Charles A. Methods and compositions for catalytic DNA exchange in a sequence specific manner
US7262174B2 (en) * 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
EP1408109B1 (en) * 2001-07-16 2008-07-09 Fuyuki Ishikawa Novel method for the induction of cellular senescence and method for screening anti-aging agent
WO2003014320A2 (en) * 2001-08-10 2003-02-20 Cornell Research Foundation, Inc. Telomerase immortalized human neutral stem cells and phenotypically-restricted progenitor cells
AUPR769701A0 (en) * 2001-09-14 2001-10-11 Li, He Telomerase inhibitory peptides and uses thereof
EP1440085B8 (de) * 2001-10-18 2010-08-04 Medicyte GmbH Transiente immortalisierung von zellen durch onkogenproteine oder telomerproteine
CA2478681A1 (en) * 2001-10-22 2003-05-01 University Of Rochester Telomerase interference
WO2003038076A1 (en) * 2001-10-31 2003-05-08 Renomedix Institute Inc. Immortalized mesenchymal cells and utilization thereof
EP1463803B1 (en) 2001-12-07 2018-02-14 Asterias Biotherapeutics, Inc. Hematopoietic cells from human embryonic stem cells
GB2399823B (en) 2001-12-07 2006-02-15 Geron Corp Islet cells from primate pluripotent stem cells
DE10163130B4 (de) * 2001-12-20 2009-05-14 Cyto Tools Gmbh Apoptotisch wirksame Peptide und diese umfassende pharmazeutische Zusammensetzungen
AU2002357613A1 (en) * 2001-12-21 2003-07-09 Shuichi Kaneko Method of detecting antitelomerase antibody
GB0200929D0 (en) * 2002-01-16 2002-03-06 Univ Glasgow Tissue rejection
CA2473741C (en) * 2002-01-18 2015-12-22 Morphotek, Inc. A method for generating engineered cells for locus specific gene regulation and analysis
US20030175961A1 (en) * 2002-02-26 2003-09-18 Herron G. Scott Immortal micorvascular endothelial cells and uses thereof
US20050106729A1 (en) * 2002-05-03 2005-05-19 Mark Irvin Rosenblatt Gene transfer methods and compositions
AU2003239901A1 (en) * 2002-05-28 2003-12-12 Kathy M. Ensrud Crisp polypeptides as contraceptives and inhibitors of sperm capacitation
US7294708B2 (en) * 2002-05-31 2007-11-13 Beijing Institute Of Biotechnology Telomerase reverse transcriptase fragments and uses thereof
AU2003267967B2 (en) * 2002-06-18 2008-11-20 Zymogenetics, Inc. Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
US7285415B2 (en) 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
AU2003290689A1 (en) 2002-11-08 2004-06-03 Kyowa Hakko Kirin Co., Ltd. Transgenic ungulates having reduced prion protein activity and uses thereof
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
WO2004099385A2 (en) * 2003-04-30 2004-11-18 Duke University Telomere elongation
ZA200509846B (en) 2003-06-23 2007-04-25 Geron Corp Compositions and methods for increasing telomerase activity
US20070274969A1 (en) * 2003-09-12 2007-11-29 Thomas Roberts Immortalization of Mammalian Cells
EP1522858A1 (en) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
CA2563064A1 (en) 2004-04-22 2005-11-10 Kirin Beer Kabushiki Kaisha Transgenic animals and uses thereof
WO2005108598A1 (en) 2004-05-11 2005-11-17 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
JP2008508888A (ja) * 2004-08-05 2008-03-27 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 細胞活性化のための方法および組成物
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
JP2006242618A (ja) * 2005-03-01 2006-09-14 Univ Of Tokyo 組織ｆｉｓｈ法によるテロメア量を指標とした癌の診断
JP4635196B2 (ja) * 2005-03-04 2011-02-16 国立大学法人広島大学 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法
CN101180397A (zh) * 2005-03-09 2008-05-14 得克萨斯大学体系董事会 用于癌症治疗基因的肿瘤选择性和高效率表达的新型hTMC启动子和载体
JP2008543277A (ja) * 2005-05-11 2008-12-04 ジェネティック テクノロジーズ リミテッド 胎児細胞を富化する方法
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
WO2007071339A1 (en) 2005-12-21 2007-06-28 Universite Catholique De Louvain Isolated liver stem cells
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
WO2008002285A1 (en) * 2006-06-26 2008-01-03 Science Applications International Corporation Igy antibodies to human telomerase reverse transcriptase
US20080131442A1 (en) * 2006-06-26 2008-06-05 Science Applications International Corporation IgY antibodies to human telomerase reverse transcriptase
AU2013203229C1 (en) * 2006-07-28 2015-10-29 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
KR101710981B1 (ko) * 2006-07-28 2017-02-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
EP2076531B1 (en) * 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
PL3255061T3 (pl) 2006-11-03 2021-12-06 The Board Of Trustees Of The Leland Stanford Junior University Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia
EP1994942A1 (en) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
EP2249718B1 (en) 2008-01-14 2019-09-18 Conventus Orthopaedics, Inc. Apparatus for fracture repair
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
EP2421955A4 (en) 2009-04-21 2012-10-10 Genetic Technologies Ltd METHODS OF OBTAINING F TAL GENETIC MATERIAL
CA2767825A1 (en) * 2009-07-09 2011-01-13 Janssen Biotech, Inc. Cardiac tissue-derived cells
WO2011088172A1 (en) 2010-01-15 2011-07-21 Brenzel Michael P Rotary-rigid orthopaedic rod
CN105534561B (zh) 2010-01-20 2018-04-03 康文图斯整形外科公司 用于骨接近和骨腔准备的装置及方法
US9657068B2 (en) 2010-02-16 2017-05-23 Ultimovacs As Telomerase polypeptide vaccine for treating cancer
US9249452B2 (en) * 2010-02-26 2016-02-02 Zhu Zhen Pirot Method of detecting and assaying telomerase activity of telomerase bound by anti-telomerase antibodies
EP2544608A4 (en) 2010-03-08 2017-02-22 Conventus Orthopaedics, Inc. Apparatus and methods for securing a bone implant
CN102933704A (zh) 2010-04-08 2013-02-13 爱丁堡大学管理处 软骨祖细胞、用于细胞衍生的方案和其用途
WO2012026309A1 (ja) * 2010-08-23 2012-03-01 公立大学法人横浜市立大学 抗ｐａｄ４抗体医薬の創成
CN102093980B (zh) * 2010-12-10 2013-04-17 梁伟国 永生化人椎间盘髓核细胞体系的制备方法
US8420617B2 (en) * 2011-03-11 2013-04-16 Biocell Laboratories Multiantivirus compound, composition and method for treatment of virus diseases
CN102676518B (zh) * 2012-02-27 2013-09-18 华侨大学 一种新型抗肿瘤amiRNA序列及其应用
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
CN108841802B (zh) * 2012-05-11 2023-06-09 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
KR101873773B1 (ko) * 2012-05-11 2018-08-02 주식회사 젬백스앤카엘 류마티즘 관절염 예방 또는 치료 조성물
CN108624654A (zh) * 2012-06-27 2018-10-09 新泽西鲁特格斯州立大学 通过使用流式细胞术的rna测量快速检测t细胞活化
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN110028554B (zh) * 2012-09-19 2023-04-07 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
CN104837859B (zh) * 2012-09-19 2019-02-22 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
KR102166542B1 (ko) 2012-09-28 2020-10-16 주식회사 젬백스앤카엘 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
KR102106756B1 (ko) 2012-12-13 2020-05-06 주식회사 젬백스앤카엘 자외선에 의한 피부 손상 예방 또는 치료용 조성물
KR102093093B1 (ko) 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
EP2959005B1 (en) 2013-02-22 2021-10-06 The Board of Trustees of the Leland Stanford Junior University Medical use relating to telomere extension
WO2014154905A1 (en) 2013-03-28 2014-10-02 Invectys A cancer vaccine for dogs
WO2014154904A1 (en) 2013-03-28 2014-10-02 Invectys A cancer vaccine for cats
KR102423106B1 (ko) 2013-06-11 2022-07-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
EA035485B1 (ru) 2013-10-28 2020-06-24 Инвектис Электроперенос генов в клетки кожи
HUE047898T2 (hu) 2013-10-28 2020-05-28 Invectys Telomerázt kódoló DNS vakcina
EP2871235A1 (en) * 2013-11-07 2015-05-13 Centre National de la Recherche Scientifique (CNRS) New methods to produce active hTERT
CA2969316A1 (en) 2013-12-12 2015-06-18 Conventus Orthopaedics, Inc. Tissue displacement tools and methods
KR102166549B1 (ko) 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
ES2945588T3 (es) 2014-08-26 2023-07-04 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
WO2017079419A1 (en) 2015-11-05 2017-05-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
SG11201805621SA (en) 2016-01-19 2018-08-30 Pfizer Cancer vaccines
BR112019015342A2 (pt) 2017-01-30 2020-03-10 The Board Of Trustees Of The Leland Stanford Junior University Regime de condicionamento não genotóxico para o transplante de células-tronco
US10631881B2 (en) 2017-03-09 2020-04-28 Flower Orthopedics Corporation Plating depth gauge and countersink instrument
US11351246B2 (en) 2017-05-09 2022-06-07 Invectys SAS Recombinant measles vaccine expressing hTERT
WO2019010252A2 (en) 2017-07-04 2019-01-10 Conventus Orthopaedics, Inc. Apparatus and methods for treatment of a bone
US11786557B2 (en) 2017-10-02 2023-10-17 Fred Hutchinson Cancer Center Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells
CN108715863B (zh) * 2018-05-30 2020-09-11 吉林大学 一种肿瘤靶向性载体pcTERT及其构建方法及其应用
CN110827920B (zh) * 2018-08-14 2022-11-22 武汉华大医学检验所有限公司 测序数据分析方法和设备及高通量测序方法
CN112930404A (zh) * 2018-09-05 2021-06-08 瑞德库尔有限责任公司 用于治疗剂分析的方法和系统
CN112654244B (zh) * 2018-09-06 2023-07-25 德克萨斯大学系统董事会 端粒酶全酶复合体及其使用方法
WO2020076976A1 (en) 2018-10-10 2020-04-16 Readcoor, Inc. Three-dimensional spatial molecular indexing
CN109545039A (zh) * 2019-01-15 2019-03-29 苏州大学 一种核孔复合体结构模型教具及其使用方法
WO2021007180A1 (en) 2019-07-05 2021-01-14 Case Western Reserve University Priming media and methods for stem cell culture and therapy
JP2021151979A (ja) * 2020-03-24 2021-09-30 均 石井 再生医療薬
US20220049303A1 (en) 2020-08-17 2022-02-17 Readcoor, Llc Methods and systems for spatial mapping of genetic variants
CN112063601B (zh) * 2020-09-22 2023-06-02 浙江愈方生物科技有限公司 一种灭活性端粒酶、具有其的腺病毒和人造mRNA及应用
JP2022119144A (ja) * 2021-02-03 2022-08-16 均 石井 パーキンソン病治療薬
JP2022151412A (ja) * 2021-03-23 2022-10-07 均 石井 脳卒中治療薬
CN113355303B (zh) * 2021-06-07 2023-06-16 中元汇吉生物技术股份有限公司 一种m-mlv逆转录酶突变体及其应用
EP4463151A4 (en) * 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy
CN114920802B (zh) * 2022-05-16 2023-05-23 中国地质大学（武汉） 调节端粒酶限速蛋白运动的多肽探针及其复合物和方法
CN116364195B (zh) * 2023-05-10 2023-10-13 浙大城市学院 一种基于预训练模型的微生物遗传序列表型预测方法

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US912629A (en) 1908-08-29 1909-02-16 Conrad L Stueber Foundation-top for pipe-carriers.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4254082A (en) 1978-06-12 1981-03-03 Miles Laboratories, Inc. Specific binding-adsorbent assay test means
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
JPS57502090A (enExample) 1980-07-18 1982-11-25
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US5055556A (en) 1981-10-06 1991-10-08 The Board Of Trustees Of The Leland Stanford Jr. Univ. Fluorescent conjugates for analysis of molecules and cells
JPS58215453A (ja) 1982-06-09 1983-12-14 Toray Silicone Co Ltd 室温硬化後塗装可能なオルガノポリシロキサン組成物
FR2542494B1 (fr) 1983-03-08 1985-08-16 Sevylor International Combinaison protectrice, utilisable notamment en atmosphere irradiee
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5272065A (en) 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
GB8612087D0 (en) 1986-05-19 1986-06-25 Ici Plc Hybridisation probes
US5001225A (en) 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US4889806A (en) 1987-04-15 1989-12-26 Washington University Large DNA cloning system based on yeast artificial chromosomes
US5017478A (en) 1987-07-16 1991-05-21 Berlex Laboratories, Inc. Transfected cells containing plasmids having genes oriented in opposing directions and methods of using
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5093245A (en) 1988-01-26 1992-03-03 Applied Biosystems Labeling by simultaneous ligation and restriction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5075227A (en) * 1989-03-07 1991-12-24 Zymogenetics, Inc. Directional cloning
JPH02307059A (ja) 1989-05-23 1990-12-20 Seiko Instr Inc 反応容器
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
AU656720B2 (en) 1989-12-01 1995-02-16 Gene Pharming Europe Bv Production of recombinant polypeptides by bovine species and transgenic methods
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
HK1000547A1 (en) 1989-12-22 1998-04-03 Merck Serono Sa Endogenous gene expression modification with regulatory element by way of homologous recombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991012650A1 (fr) 1990-02-09 1991-08-22 Asulab S.A. Micromoteur electrostatique a champ radial realise par microfabrication photolithographique et procede de realisation d'un tel micromoteur
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
SE468913B (sv) 1990-05-16 1993-04-05 Igesto Ab Saekerhetskrok
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
KR100198659B1 (ko) 1996-05-16 1999-06-15 구본준 메모리 셀, 메모리 장치 및 그의 제조 방법
EP0566714B1 (en) 1991-10-11 1997-01-02 Promega Corporation Coupled transcription and translation in eukaryotic cell-free extract
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5639613A (en) 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5645986A (en) 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5648215A (en) 1992-05-13 1997-07-15 Board Of Regents, The University Of Texas System Telomerase diagnostic methods
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US6107062A (en) 1992-07-30 2000-08-22 Inpax, Inc. Antisense viruses and antisense-ribozyme viruses
GB2273932A (en) 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
JPH08508636A (ja) 1993-01-27 1996-09-17 オンコール インコーポレーテッド 核酸配列の増幅
US6140087A (en) 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6120764A (en) 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
WO1995013382A1 (en) * 1993-11-12 1995-05-18 Geron Corporation Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
ATE308554T1 (de) * 1994-07-07 2005-11-15 Geron Corp Säugetier-telomerase
US5597697A (en) 1994-09-30 1997-01-28 Diamond; Paul Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases
US5698686A (en) * 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
WO1996019580A2 (en) * 1994-12-19 1996-06-27 Cold Spring Harbor Laboratory Telomerase protein component
WO1997015687A1 (en) 1995-06-07 1997-05-01 Geron Corporation Telomerase activity assays
US5741677A (en) 1995-06-07 1998-04-21 Geron Corporation Methods for measuring telomere length
AU701903B2 (en) 1995-06-07 1999-02-11 Cold Spring Harbor Laboratory Essential oligonucleotides of vertebrate telomerase
US5722998A (en) 1995-06-07 1998-03-03 Intermedics, Inc. Apparatus and method for the control of an implantable medical device
JP3372258B2 (ja) 1995-08-04 2003-01-27 インターナシヨナル・ビジネス・マシーンズ・コーポレーシヨン リソグラフィ・プロセス用のスタンプ
US6545133B1 (en) 1995-08-04 2003-04-08 Geron Corporation Methods for purifying telomerase
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6517834B1 (en) 1995-08-04 2003-02-11 Geron Corporation Purified telomerase
JPH09154575A (ja) 1995-10-04 1997-06-17 Soosei:Kk テロメラーゼ
JPH09164575A (ja) 1995-12-13 1997-06-24 Japan Steel Works Ltd:The 流れ模様を有する樹脂板の製造方法およびその装置
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US5770422A (en) * 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US5747317A (en) 1996-07-08 1998-05-05 Tularik Inc. Human telomerase RNA interacting protein gene
US5724021A (en) 1996-07-09 1998-03-03 Stephen C. Perrone Self-contained, programmable, time interval alarm reminder device for eyedrop medication administration and a means for affixing such to eyedrop/medication container
AUPO181296A0 (en) 1996-08-21 1996-09-12 Commonwealth Scientific And Industrial Research Organisation Manipulation of proanthocyanidin biosynthesis
WO1998007838A1 (en) 1996-08-21 1998-02-26 Mitsubishi Chemical Corporation Higher animal telomerase protein and gene encoding the same
AU4030697A (en) 1996-08-28 1998-03-19 Shonen Yoshida Proteins having telomerase activity
DE19638482A1 (de) 1996-09-20 1998-04-02 Bosch Gmbh Robert Verfahren zur Auswahl einer Sendefrequenz
FI990655A7 (fi) * 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6777203B1 (en) 1997-11-19 2004-08-17 Geron Corporation Telomerase promoter driving expression of therapeutic gene sequences
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6767719B1 (en) 1997-11-26 2004-07-27 Geron Corporation Mouse telomerase reverse transcriptase
US5890326A (en) 1996-11-06 1999-04-06 Hill-Rom, Inc. Head wall for a hospital room
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
EP0942991A2 (en) 1996-11-26 1999-09-22 Baylor College Of Medicine Identification of inhibitors that prevent access of telomerase to chromosomal terminus
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
US6617119B2 (en) 1997-02-21 2003-09-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein
ES2208895T3 (es) * 1997-04-04 2004-06-16 Geron Corporation Telomerasa purificada.
US6485789B1 (en) 1997-04-14 2002-11-26 3M Innovative Properties Company Fluorochemical composition containing a condensation product of a fluorochemical polyether and a poly-isocyanate to impart stain release properties to a substrate
US20050013825A1 (en) 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US6201830B1 (en) 1997-06-11 2001-03-13 Texas Instruments Incorporated Low computation idle transmission method for DSL modems
EP0990037A2 (de) * 1997-06-20 2000-04-05 Bayer Ag Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung
CA2294782A1 (en) 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
WO1999027113A1 (en) 1997-11-26 1999-06-03 Geron Corporation Mouse telomerase reverse transcriptase
DE19757984A1 (de) 1997-12-24 1999-07-01 Bayer Ag Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung
EP1045027B1 (en) 1998-01-08 2006-05-31 Chugai Seiyaku Kabushiki Kaisha Novel gene having reverse transcriptase motif
GB9801902D0 (en) 1998-01-29 1998-03-25 Cancer Res Campaign Tech A gene promoter
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US6069471A (en) 1998-05-14 2000-05-30 Intel Corporation Dynamic set point switching regulator
WO1999063945A2 (en) 1998-06-12 1999-12-16 Sloan-Kettering Institute For Cancer Research Vaccination strategy to prevent and treat cancers
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
ES2220448T3 (es) 1999-02-04 2004-12-16 Geron Corporation Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa.
EP1171612A2 (en) 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-specific cancer vaccine
WO2000073420A2 (en) 1999-06-02 2000-12-07 Whitehead Institute For Biomedical Research Creation of human tumorigenic cells and uses therefor
US6354941B2 (en) 1999-11-03 2002-03-12 516 Holdings Electronic system for a game of chance
JP2004527449A (ja) 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
US7262174B2 (en) 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
JP2002348474A (ja) 2001-05-23 2002-12-04 Dow Corning Toray Silicone Co Ltd ポリオルガノシロキサンマイクロエマルジョン組成物および化粧料原料
WO2003038047A2 (en) 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
US7294708B2 (en) 2002-05-31 2007-11-13 Beijing Institute Of Biotechnology Telomerase reverse transcriptase fragments and uses thereof
KR100705868B1 (ko) 2003-05-06 2007-04-10 후지 덴키 디바이스 테크놀로지 가부시키가이샤 반도체 장치 및 그 제조 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081042A (ja) * 1996-10-01 2001-03-27 Geron Corp ヒトテロメラーゼ触媒性サブユニット
JP2009040779A (ja) * 1996-10-01 2009-02-26 Geron Corp ヒトテロメラーゼ触媒性サブユニット

Also Published As

Publication number Publication date
DE841396T1 (de) 1998-09-24
ATE552341T1 (de) 2012-04-15
EP1783139A2 (en) 2007-05-09
ATE245194T1 (de) 2003-08-15
JP4852576B2 (ja) 2012-01-11
FI990655L (fi) 1999-03-24
DE69723531T3 (de) 2012-09-06
JP2009040779A (ja) 2009-02-26
WO1998014593A3 (en) 1999-02-18
JP2001523947A (ja) 2001-11-27
SG94355A1 (en) 2003-02-18
JP2001510985A (ja) 2001-08-07
GB9720890D0 (en) 1997-12-03
GB2321642A (en) 1998-08-05
JPH10234384A (ja) 1998-09-08
HK1156967A1 (zh) 2012-06-22
NZ334709A (en) 2001-06-29
GB2321642B8 (en) 2006-08-22
JPH11313689A (ja) 1999-11-16
CA2645721A1 (en) 1998-04-09
NO20053120D0 (no) 2005-06-24
KR20000048839A (ko) 2000-07-25
JP4070331B2 (ja) 2008-04-02
NO991588D0 (no) 1999-03-31
WO1998014593A2 (en) 1998-04-09
FR2757177A1 (fr) 1998-06-19
DE69739675D1 (de) 2010-01-07
DE69739497D1 (de) 2009-08-27
KR100530483B1 (ko) 2006-01-09
BR9712254A (pt) 2000-01-18
GB2317891A (en) 1998-04-08
FI990655A0 (fi) 1999-03-24
ES2205132T3 (es) 2004-05-01
DE69723531T2 (de) 2004-05-27
EP0841396A1 (en) 1998-05-13
IL129103A0 (en) 2000-02-17
JPH11253177A (ja) 1999-09-21
ES2205132T5 (es) 2012-06-18
CN102021153A (zh) 2011-04-20
EA199900355A1 (ru) 2000-08-28
EA199900349A1 (ru) 2000-06-26
GB2317891B (en) 1998-08-19
GB2317891C (en) 2015-06-24
BR9711844A (pt) 2000-01-18
EP0954585B1 (en) 2009-11-25
EP1333094A3 (en) 2005-02-09
US20090269739A1 (en) 2009-10-29
GB9804859D0 (en) 1998-04-29
EP0841396B1 (en) 2003-07-16
CA2645721C (en) 2015-05-12
CN1254376A (zh) 2000-05-24
EP0932686A2 (en) 1999-08-04
CN102021153B (zh) 2016-05-25
EP1783139A3 (en) 2007-05-23
DE69723531D1 (de) 2003-08-21
NO332085B1 (no) 2012-06-18
EP1333094B1 (en) 2012-04-04
JP2001081042A (ja) 2001-03-27
CA2267664C (en) 2013-06-11
EP1783139B8 (en) 2009-09-23
US6166178A (en) 2000-12-26
US6617110B1 (en) 2003-09-09
AU734089B2 (en) 2001-06-07
GB2321642B (en) 2000-02-09
WO1998014593A9 (en) 1999-05-14
EP1783139B1 (en) 2009-07-15
EP0841396B2 (en) 2012-04-11
EP0954585A2 (en) 1999-11-10
AU4803697A (en) 1998-04-24
FI990655A7 (fi) 1999-06-01
KR20000048820A (ko) 2000-07-25
CA2267664A1 (en) 1998-04-09
US8222392B2 (en) 2012-07-17
NO20053120L (no) 1998-04-02
CA2266752A1 (en) 1998-04-09
NO991588L (no) 1999-05-31
IL129222A0 (en) 2000-02-17
EP1333094A2 (en) 2003-08-06
CN1291231A (zh) 2001-04-11
BRPI9712254B1 (pt) 2019-01-15
ATE449851T1 (de) 2009-12-15
WO1998014592A3 (en) 1999-04-01
NO319982B1 (no) 2005-10-10
CN1291231B (zh) 2010-06-02
AU4807397A (en) 1998-04-24
EP2213740A1 (en) 2010-08-04
DE19743497A1 (de) 1998-08-20
US7517971B1 (en) 2009-04-14
WO1998014592A2 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
JP3869092B2 (ja) ヒトテロメラーゼ触媒性サブユニット
US6610839B1 (en) Promoter for telomerase reverse transcriptase
US8236774B2 (en) Human telomerase catalytic subunit
US8709995B2 (en) Method for eliciting an immune response to human telomerase reverse transcriptase
US7413864B2 (en) Treating cancer using a telomerase vaccine
HK1024505B (en) Human telomerase reverse transcriptase promoter
HK1024505A1 (en) Human telomerase reverse transcriptase promoter
AU4799201A (en) Promoter for human telomerase reverse transcriptase

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20011105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20061012

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091020

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091020

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091020

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101020

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111020

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121020

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131020

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term